Key facts
- Notable investors include Dria Ventures, Katalyst Impact Fund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for EXPIN
- ·The full record, as it builds
Funding rounds
No funding rounds for EXPIN are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EXPIN
Developer of analytical tools for precision medicine designed to broaden access to understanding and addressing environmental and lifestyle contributors to chronic disease. The company uses evidence-linked exposome analysis, tools that help clinicians and patients identify non-genetic factors influencing health, integrates data about environmental exposures and lifestyle elements with biomedical insights, supports interactive interpretation of results with clinical context, and emphasizes transparency in how findings are derived, enabling healthcare professionals, researchers, and individuals concerned with long-term health to consider often-overlooked causes of chronic conditions and inform more comprehensive, preventive care decisions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Employees
- 3
- Website
- expin.ai/
- Ownership
- Privately Held (backing)
EXPIN doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EXPIN shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EXPIN in its N-PORT filings yet. We sweep new filings monthly.